Literature DB >> 2992757

Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont.

C G Chute, E R Greenberg, J Baron, R Korson, J Baker, J Yates.   

Abstract

The authors identified all newly diagnosed lung cancer cases in New Hampshire and Vermont for the period 1973 through 1976 and abstracted clinical data on presenting symptoms and findings from their hospital records. Microscopy slides were also reviewed, when possible, to confirm cell type. The most frequent presenting symptoms were weight loss (46%) and cough (45%). Other common symptoms were dyspnea (37%), weakness (34%), chest pain (27%), and hemoptysis (27%). The presence of symptoms and findings was in general related to disease stage but bore little relationship to cell type. These results differ from those of previously reported case series that were based on surgical, radiation therapy, or Veterans Hospital groups, but the current data agree closely with those from another population-based series in Finland.

Entities:  

Mesh:

Year:  1985        PMID: 2992757     DOI: 10.1002/1097-0142(19851015)56:8<2107::aid-cncr2820560837>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

1.  Prognostic significance of 18 F-fluorodeoxyglucose - positron emission tomography after treatment in patients with limited stage small cell lung cancer.

Authors:  Adedayo A Onitilo; Jessica M Engel; Jennifer M Demos; Bickol Mukesh
Journal:  Clin Med Res       Date:  2008-09-18

2.  Localizing small lung lesions in video-assisted thoracoscopic surgery via radiofrequency identification marking.

Authors:  Yojiro Yutaka; Toshihiko Sato; Jitian Zhang; Koichi Matsushita; Hiroyuki Aiba; Yusuke Muranishi; Yasuto Sakaguchi; Teruya Komatsu; Fumitsugu Kojima; Tatsuo Nakamura; Hiroshi Date
Journal:  Surg Endosc       Date:  2016-12-23       Impact factor: 4.584

3.  Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer.

Authors:  Arkadiusz Z Dudek; Krzysztof Leśniewski-Kmak; Robin L Bliss; Claudio Brunstein; Debra L Condon; Robert A Kratzke
Journal:  Lung       Date:  2005 Jan-Feb       Impact factor: 2.584

4.  Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada.

Authors:  S J Seung; M Hurry; R N Walton; W K Evans
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.677

Review 5.  Epidemiology and management of common pulmonary diseases in older persons.

Authors:  Kathleen M Akgün; Kristina Crothers; Margaret Pisani
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-02-15       Impact factor: 6.053

6.  Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer.

Authors:  Jae Ho Chung; Moo Suk Park; Young Sam Kim; Joon Chang; Joo Hang Kim; Sung Kyu Kim; Se Kyu Kim
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

Review 7.  Management of small-cell lung cancer: incremental changes but hope for the future.

Authors:  Christine L Hann; Charles M Rudin
Journal:  Oncology (Williston Park)       Date:  2008-11-30       Impact factor: 2.990

Review 8.  Clinical mimics: an emergency medicine focused review of pneumonia mimics.

Authors:  Drew Alan Long; Brit Long; Alex Koyfman
Journal:  Intern Emerg Med       Date:  2018-03-26       Impact factor: 3.397

Review 9.  Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

Authors:  M Reck; F Barlesi; L Crinò; C I Henschke; D Isla; S Stiebeler; D R Spigel
Journal:  Ann Oncol       Date:  2011-11-04       Impact factor: 32.976

10.  Radiotherapeutic Care of Patients With Stage IV Lung Cancer with Thoracic Symptoms in the Veterans Health Administration.

Authors:  Ruchika Gutt; Sheetal Malhotra; Drew Moghanaki; Alice V Cheuk; Lori Hoffman-Hogg; Maria Kelly; Helen Fosmire; George Dawson
Journal:  Fed Pract       Date:  2020-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.